Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Details
Category: Globe NewsWire News Distribution Service

TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. In the…


Posted: 2024-09-21 08:15:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | teva | presents | phase


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia - Newscast

Regeneron/Teva pain drug fasinumab on target in phase 3

Wed, 18 Dec 2024 16:00:00 GMT Regeneron and Teva have announced positive top-line phase 3 results from their fasinumab, as the companies chase Pfizer and Lilly in the race to market a new class of non-opioid painkillers.

Teva Pharmaceutical Industries Limited (TEVA)

Wed, 18 Dec 2024 12:59:00 GMT An archiv For an accessible version of this Press Release, please visit ... in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis ...

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Wed, 18 Dec 2024 10:29:00 GMT Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.

TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals?

Wed, 18 Dec 2024 01:32:30 GMT Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could transform treatment options and reshape the market.

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

Tue, 17 Dec 2024 10:20:20 GMT Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.


Blow Us A Whistle